Drug Trial Radar · NCT02616302
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Feb 20, 2023
Primary completion
Jul 21, 2026
Study completion Jul 21, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of GERD include pain in the stomach or throat, difficulty eating, and throwing up. Symptomatic nonerosive GERD is a condition where people have the symptoms of GERD but the esophagus has not been damaged. People of all ages can have GERD. The causes of GERD in children are similar to those in adults and teenagers. Dexlansoprazole is a medicine that has been shown to help relieve the symptoms of GERD in adults and teenagers. This study aims to find out if dexlansoprazole doses given to children with symptomatic nonerosive GERD, based on their body weight, helps them feel better.
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
DexlansoprazoleDrug
Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Days Without Hurting or Burning in the Stomach, Chest or Throat Over the 12 Weeks of TreatmentTime frame: Up to 12 weeks
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
Childrens Center for Digestive Health Care, LLC
Mobile, Alabama
University of Utah/ Primary Childrens Hospital
San Francisco, California
GI For Kids
Atlanta, Georgia
Childrens Hospital of The Kings Daughters
Jackson, Mississippi
The University of Chicago
Cleveland, Ohio
National Research Centers
Norfolk, Virginia
Women and Children's Health Research Institute
Edmonton, Alberta, Canada
London Health Sciences Centre Children's Hospital
London, Ontario, Canada
Hospital Universitario San Ignacio
Bogotá, Colombia
Fundacion Valle del Lili
Cali, Colombia
Centro Medico Imbanaco de Cali S.A
Cali, Colombia
El Cielo Medical Center
Puebla City, Mexico
SMIQ, S. DE R.L. DE C.V. Queretaro
Querétaro, Mexico
Boca Clinical Trials Mexico S.C.
Querétaro, Putumayo, Mexico
Clinical Research Institute S.C.
Tlalnepantla, State of Mexico, Mexico
In Vivo Osrodek Badan Klinicznych
Bydgoszcz, Poland
Instytut "Pomnik - Centrum Zdrowia Dziecka", Oddzial Gastroenterologii, Hepatologii, Zaburzen odzywiania i Pediatrii
Warsaw, Poland
Gabinet Lekarski Bartosz Korczowski
Rzeszów, PL, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.